Latest Headlines

Latest Headlines

Illumina finds match in Australian genomics company for transplant sequencing work

Illumina is off to a racing start in 2016, and the pace isn't showing any signs of slowing. The company is snatching up Conexio Genomics to get its hands on Conexio's transplant genotyping products, a couple of weeks after it unveiled its liquid biopsy spinoff and expanded genomics offerings.

Sony, Carlyle Group, KKR among bidders for Toshiba's imaging unit, expected to fetch $3B+

Toshiba appears on track to earn more than $3 billion from the sale of its medical device unit to help it recover from an accounting scandal, as the list of companies bidding on Toshiba Medical Systems grows, just prior to the Friday deadline.

Facing extinction, MannKind is reportedly looking to sell itself

Struggling drugmaker MannKind is looking for a way out of its perilous financial situation, according to Reuters, scouting for a buyer in the wake of ex-partner Sanofi's decision to abandon the company and its inhaled insulin.

J&J; hints at 'bold steps' in device deals in 2016, details 5 device collaborations

After disclosing a major restructuring of its medical device business last week, Johnson & Johnson tried to refocus on the future of that group on its annual earnings call. It emphasized doing more deals to acquire platforms for growth, as well as funneling more resources to high revenue growth device groups.

Indian pharma mulls deal for U.S. injectables maker Sagent Pharma

U.S. injectables maker Sagent Pharmaceuticals is considering putting itself on the chopping block, and if or when it does, at least 5 Indian drugmakers could come calling.

Struggling XenoPort rumored to consider a sale

XenoPort, a month removed from deep job cuts, is looking to sell itself, according to Reuters, reaching out to potential acquirers after a string of R&D; disappointments.

BioClinica buys into cost management with its latest deal

Acquisitive CRO BioClinica bought a firm that specializes in handling the financial side of clinical trials, picking up technology that automates how sponsors and contractors pay for studies.

Medicines Co. jumps on rumors of a multibillion-dollar buyout

Drugmaker the Medicines Company saw its shares rise as high as 14% on rumors that the company may be up for sale.

Acorda bags PhIII Parkinson's drug in $363M Biotie buyout

Acorda Therapeutics has swooped in to buy Finland's Biotie for $363 million in cash, snagging a Phase III Parkinson's drug that is being lined up to follow its leading experimental drugs into the neurology market.

Second activist investor buys 5% stake in HeartWare, putting Valtech deal in doubt

HeartWare's acquisition of Israeli cardiac implant maker Valtech Cardio is now in even greater jeopardy. Reuters reports that a second group of activist investors, led by former J.P. Morgan CFO Doug Braunstein, purchased a 5% stake in the struggling company in hopes of blocking the transaction.